Victor M Villalobos|D Ross Camidge - JoVE Visualize

Showing results (61-70 of 279) with videos related to

Pageof 28

Sort By:

Biotechnology Progress|March 31, 2009

Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain protease biosensorsSeth T Gammon, Victor M Villalobos, Mikhail Roshal, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2016

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 AlterationsRafael Caparica, Cheng Tzu Yen, Renata Coudry, et al.

Lung Cancer (Amsterdam, Netherlands)|March 21, 2021

Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)Maria Rosario Garcia Campelo, Huamao M Lin, Yanyan Zhu, et al.

International Journal of Radiation Oncology, Biology, Physics|January 28, 2014

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinibGregory N Gan, Andrew J Weickhardt, Benjamin Scheier, et al.

Journal for Immunotherapy of Cancer|October 16, 2024

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironmentsAung Naing, Danny Khalil, Oliver Rosen, et al.

Eclinicalmedicine|June 24, 2022

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumoursDaniel D Karp, D Ross Camidge, Jeffery R Infante, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2016

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung CancerRafal Dziadziuszko, Anh T Le, Anna Wrona, et al.

Journal of the National Cancer Institute|August 10, 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapiesJason J Luke, Geoffrey R Oxnard, Cloud P Paweletz, et al.

Bioconjugate Chemistry|March 20, 2003

Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptakeSeth T Gammon, Victor M Villalobos, Julie L Prior, et al.

Clinical Lung Cancer|September 11, 2018

First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic SignificanceWade T Iams, Hui Yu, Yu Shyr, et al.

Pageof 28

Showing results (61-70 of 279) with videos related to

Sort By:

Pageof 28

Biotechnology Progress|March 31, 2009

Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain protease biosensorsSeth T Gammon, Victor M Villalobos, Mikhail Roshal, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2016

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 AlterationsRafael Caparica, Cheng Tzu Yen, Renata Coudry, et al.

Lung Cancer (Amsterdam, Netherlands)|March 21, 2021

Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)Maria Rosario Garcia Campelo, Huamao M Lin, Yanyan Zhu, et al.

International Journal of Radiation Oncology, Biology, Physics|January 28, 2014

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinibGregory N Gan, Andrew J Weickhardt, Benjamin Scheier, et al.

Journal for Immunotherapy of Cancer|October 16, 2024

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironmentsAung Naing, Danny Khalil, Oliver Rosen, et al.

Eclinicalmedicine|June 24, 2022

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumoursDaniel D Karp, D Ross Camidge, Jeffery R Infante, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2016

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung CancerRafal Dziadziuszko, Anh T Le, Anna Wrona, et al.

Journal of the National Cancer Institute|August 10, 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapiesJason J Luke, Geoffrey R Oxnard, Cloud P Paweletz, et al.

Bioconjugate Chemistry|March 20, 2003

Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptakeSeth T Gammon, Victor M Villalobos, Julie L Prior, et al.

Clinical Lung Cancer|September 11, 2018

First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic SignificanceWade T Iams, Hui Yu, Yu Shyr, et al.

Pageof 28